Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia

Schizophrenia Research

Volumn 120, Issue 1-3, 2010, Pages 199-203

  Docherty, J P ^a   Baker, R A ^b   Eudicone, J ^b   Mathew, S ^c   Marcus, R N ^b   McQuade, R D ^c   Mankoski, R ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Functioning; Relationships; Social

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSOCIAL SUBSCALE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIAL INTERACTION; ADOLESCENT; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; MIDDLE AGED; PSYCHOLOGY; PSYCHOMOTOR AGITATION; SOCIAL BEHAVIOR DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL BEHAVIOR DISORDERS; YOUNG ADULT;

EID: 77954142170     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.040     Document Type: Article

References (26)

1. Baran X., Docherty J. The A-effect of aripiprazole. Presented at the American Psychiatric Association meeting 2008, Washington, May 3-8 2008.
2. Barrowclough C., Tarrier N. Social functioning in schizophrenic patients. I. The effects of expressed emotion and family intervention. Soc. Psychiatry Psychiatr. Epidemiol. 1990, 25(3):125-129.
3. Bellack A.S., Green M.F., Cook J.A., Fenton W., Harvey P.D., Heaton R.K., Laughren T., Leon A.C., Mayo D.J., Patrick D.L., Patterson T.L., Rose A., Stover E., Wykes T. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr. Bull. 2007, 33(3):805-822.
4. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 2002, 302(1):381-389.
5. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002, 346(1):16-22.
6. Girgis, R., Merrill, D., Vorel, S., Kim, E., Portland, K., You, M., Pikalov, A., Whitehead, R. and Lieberman, J., submitted for publication. Aripiprazole versus haloperidol treatment in early-stage schizophrenia. J. Psychiatr. Res.
7. Grant C., Addington J., Addington D., Konnert C. Social functioning in first- and multiepisode schizophrenia. Can. J. Psychiatry 2001, 46(8):746-749.
8. Janicak P.G., Glick I.D., Marder S.R., Crandall D.T., McQuade R.D., Marcus R.N., Eudicone J.M., Assuncao-Talbott S. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J. Clin. Psychiatry 2009, 70(1):25-35.
9. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur. J. Pharmacol. 2002, 441(3):137-140.
10. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 2004, 483(1):45-53.
11. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2002, 63(9):763-771.
12. Kane J.M., Meltzer H.Y., Carson W.H., McQuade R.D., Marcus R.N., Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry 2007, 68(2):213-223.
13. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M., Archibald D., Ingenito G., Marcus R., Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol 2003, 6(4):325-337.
14. Kerwin R., Millet B., Herman E., Banki C.M., Lublin H., Pans M., Hanssens L., L'Italien G., McQuade R.D., Beuzen J.N. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole (STAR) Study. Eur. Psychiatry 2007, 22(7):433-443.
15. Kim, E., Eudicone, J., Portland, K. and Pikalov, A., 2007. Efficacy of aripiprazole versus haloperidol in early episode schizophrenia. Presented at the American Psychiatric Association 160th Annual Meeting, San Diego, CA, May 19-24, 2007. NR283.
16. Marder S.R., Glynn S.M., Wirshing W.C., Wirshing D.A., Ross D., Widmark C., Mintz J., Liberman R.P., Blair K.E. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am. J. Psychiatry 2003, 160(8):1405-1412.
17. Mizrahi R., Mamo D., Rusjan P., Graff A., Houle S., Kapur S. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int. J. Neuropsychopharmacol 2009, 12(5):715-721.
18. Pigott T.A., Carson W.H., Saha A.R., Torbeyns A.F., Stock E.G., Ingenito G.G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 2003, 64(9):1048-1056.
19. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60(7):681-690.
20. Potkin S.G., Weiden P.J., Loebel A.D., Warrington L.E., Watsky E.J., Siu C.O. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int. J. Neuropsychopharmacol 2009, 12(9):1233-1248.
21. Purnine D.M., Carey K.B., Maisto S.A., Carey M.P. Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders. J. Nerv. Ment. Dis. 2000, 188(10):653-661.
22. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003, 28(8):1400-1411.
23. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., Kikuchi T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 2005, 515(1-3):10-19.
24. Tadori Y., Forbes R.A., McQuade R.D., Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur. J. Pharmacol. 2008, 597(1-3):27-33.
25. Wolf J., Janssen F., Lublin H., Salokangas R.K., Allain H., Smeraldi E., Bernardo M., Millar H., Pans M., Adelbrecht C., Laughton J., Werner C., Maier W. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr. Med. Res. Opin. 2007, 23(10):2313-2323.
26. Yager J.A., Ehmann T.S. Untangling social function and social cognition: a review of concepts and measurement. Psychiatry 2006, 69(1):47-68.